타이로신키나아제 억제제의 임상적으로 유의한 약물상호작용 정보 일관성 분석

다국어 초록 (Multilingual Abstract)

Background: Drug-drug interactions (DDIs) in patients using oral anticancer treatment are more common than in those using injectable anticancer agents. In addition, DDIs related to anticancer treatment are known to cause clinically significant outcomes, such as treatment failure and severe toxicity. To prevent these negative outcomes, significant DDIs are monitored and managed using the information provided in drug databases. We aimed to evaluate the consistency of information on clinically significant DDIs for tyrosine kinase inhibitors (TKIs) between representative drug databases. Methods: We selected clinically significant DDIs involving medications that are co-prescribed with TKIs and met the following criteria: the severity level of DDIs was equal or greater than “D” in Lexicomp® or “major” in Micromedex®. We then analyzed the consistency of the severity classification and evidence level between the drug databases. Spearman’s correlation coefficient was used to identify the relationship between DDI information in the drug databases. Results: In total, 627 DDI pairs were identified as clinically significant; information on these was provided by Lexicomp® and Micromedex® for 571 and 438 pairs, respectively, and both drug databases provided information on 382 DDI pairs. There was no correlation between the severity and evidence level of DDIs provided in the two databases; Spearman’s correlation coefficient for Lexicomp® and Micromedex® was -0.009 (p=0.861) and -0.064 (p=0.209), respectively. Conclusion: To judge the significance of DDIs, healthcare providers should consider that the information on DDIs may be different between drug information databases; hence, clinical factors must be considered concurrently.

목차 (Table of Contents)

• ABSTRACT
• 연구방법
• TKIs 및 약물상호작용 조합의 선정
• 약물상호작용 조합의 분류
• 통계분석
• 연구 결과
• 의약정보 정보원 간 정보 비교
• 국내 허가사항과 의약정보 정보원 비교
• 고찰
• 결론
• 감사의 말씀
• 이해상충
• References

참고문헌 (Reference)

1 Bowlin SJ, "Twelvemonth frequency of drug-metabolizing enzyme and transporterbased drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents" 88 (88): 139-148, 2013

2 Alfred P. JDB, "Social Science Research Design and Statistics: A Practitioner’s Guide to Research Methods and IBM SPSS analysis" Watetree Press LLC

3 Kim SH, "Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents:a population-based study" 2019

4 van Leeuwen RW, "Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs" 108 (108): 1071-1078, 2013

5 Acton EK, "Poor concordance among drug compendia for proposed interactions between enzymeinducing antiepileptic drugs and direct oral anticoagulants" 28 (28): 1534-1538, 2019

6 Hersh LR, "Polypharmacy in the Geriatric Oncology Population" 19 (19): 73-, 2017

7 Gay C, "Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors : A focus on cytochrome P450, transporters, and acid suppression therapy" 35 (35): 259-280, 2017

8 Meslin SMM, "Evaluation of clinical relevance of drug-drug interaction alerts prior to implementation" 9 (9): 849-855, 2018

9 van Leeuwen RW, "Drug-drug interactions with tyrosine-kinase inhibitors : a clinical perspective" 15 (15): e315-e326, 2014

10 Keller KL, "Drug-drug interactions in patients receiving tyrosine kinase inhibitors" 24 (24): 110-115, 2018

11 Blower P, "Drug-drug interactions in oncology : why are they important and can they be minimized" 55 (55): 117-142, 2005

12 Ekstein D, "Drug interactions involving antiepileptic drugs : assessment of the consistency among three drug compendia and FDA-approved labels" 44 : 218-224, 2015

13 MHLW, "Drug interaction guideline for drug development and labeling recommendations (draft for public comment)"

14 U.S. Food & Drug Administration, "Drug development and drug interactions: Table of substrates, inhibitors and inducers"

15 Liu X, "Consistency of psychotropic drugdrug interactions listed in drug monographs" 57 (57): 698-703.e692, 2017

16 Yoon D, "Consistency of listed indications and contraindications between the U.S., the U.K., Japan, and Korea on prescription drug labels" 98 : 168-170, 2018

17 Vitry AI, "Comparative assessment of four drug interaction compendia" 63 (63): 709-714, 2007

18 Wong CM, "Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents : profiling and comparison of two drug compendia" 42 (42): 1737-1748, 2008

19 Jeong S, "Assessment of consistency of drug interaction information in drug labels among the US, the UK, China, Japan, and Korea" 105 (105): 505-514, 2019